Athena Hits Ambry With 4 Genetic Testing Patent Suits

By Allison Grande

Law360, New York (November 19, 2009, 2:10 PM ET) -- Athena Diagnostics Inc., the sublicensee of patents related to genetic tests for the detection and diagnosis of certain forms of diabetes, has accused rival laboratory Ambry Genetics Corp. of infringing four of those patents in its testing.

In four separate suits filed Wednesday in the U.S. District Court for the District of Massachusetts, Athena claims that Ambry performs endocrine and metabolism molecular disease tests at its facility that infringe patents obtained from three research and academic institutions through an arrangement with Correlagen Diagnostics Inc.

In June...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles

Sections

Law Firms Mentioned